Painful Intercourse: What Could Be Causing It

How Common Is Painful Intercourse?

Dyspareunia is one of the most frequently reported sexual health complaints across all age groups. Population-based data from the National Health and Social Life Survey found that 14.4% of U.S. women aged 18 to 59 reported pain during intercourse within the prior 12 months [1]. Rates climb higher after menopause, where genitourinary syndrome of menopause (GSM) affects roughly 50% of postmenopausal women and painful sex is the chief complaint that drives many of them to seek care [2].

The condition is not exclusive to women. A 2015 British probability survey (Natsal-3, N=6,669 men) found that 1.9% of sexually active men reported frequent pain during intercourse in the preceding year, with phimosis, Peyronie disease, and chronic prostatitis accounting for the majority of cases [3]. These numbers almost certainly undercount true prevalence; a 2020 narrative review in the Journal of Sexual Medicine noted that fewer than half of affected individuals raise the symptom with a clinician unless directly asked [4].

Pain during sex erodes quality of life. It is not a normal part of aging, and it is not something patients should simply endure. The first clinical step is classification: where does the pain occur, and when during intercourse does it start?

Superficial vs. Deep Dyspareunia: Why the Distinction Matters

Localizing pain to the vulvar vestibule and vaginal introitus (superficial) or to the deep pelvis (deep) narrows the differential by roughly half. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 states: "Differentiating superficial from deep dyspareunia is the single most useful step in the initial evaluation, because the two categories point to largely non-overlapping etiologies" [5].

Superficial dyspareunia involves pain at the vaginal opening or within the first few centimeters of the canal. Common causes include vulvovaginal atrophy from estrogen loss, provoked vestibulodynia (formerly vulvar vestibulitis syndrome), lichen sclerosus, vaginal infections such as candidiasis or trichomoniasis, and hypertonic pelvic floor muscles. Deep dyspareunia refers to pain felt with deeper penetration, typically localized behind the cervix or in the lower pelvis. Endometriosis, adenomyosis, pelvic inflammatory disease (PID), ovarian cysts, uterine fibroids, and interstitial cystitis/bladder pain syndrome are the primary deep-pain generators.

Some patients report both. That overlap pattern often points toward a centralized pain process or concurrent conditions. A 2019 cross-sectional study in Obstetrics & Gynecology (N=1,452 women presenting to vulvodynia clinics) found that 38% of participants met criteria for at least two coexisting pain diagnoses, reinforcing the need for a systematic rather than single-diagnosis workup [6].

Causes of Superficial Painful Intercourse

Vulvar and vaginal entry pain has a broad differential, but five diagnoses account for the vast majority of cases in premenopausal women.

Provoked vestibulodynia (PVD). This is the most common cause of recurrent entry dyspareunia in women under 50. It presents as a burning or sharp pain localized to the vulvar vestibule on contact (tampon insertion, speculum, or intercourse). The cotton-swab test, where a moistened swab is applied to clock-face positions around the vestibule, reproduces the pain and is diagnostic [7]. The 2024 International Society for the Study of Vulvovaginal Disease (ISSVD) consensus recognizes PVD as a distinct clinical entity with neuroproliferative and inflammatory subtypes.

Genitourinary syndrome of menopause (GSM). Estrogen decline thins the vaginal epithelium, reduces lubrication, and raises vaginal pH, creating a fragile mucosa prone to micro-tears. The 2020 North American Menopause Society (NAMS) position statement reported that low-dose vaginal estrogen resolves dyspareunia in 80-90% of GSM cases within 12 weeks [2]. Ospemifene (Osphena, 60 mg oral daily), a selective estrogen receptor modulator, is an alternative for women who prefer non-vaginal therapy [8].

Vaginismus / pelvic floor hypertonicity. Involuntary contraction of the levator ani and superficial perineal muscles can make penetration painful or impossible. A 2021 Cochrane review of pelvic floor physical therapy for vaginismus found clinically meaningful improvement in 71% of participants across six randomized trials, though heterogeneity in outcome measures limited pooled effect estimates [9].

Infections. Recurrent vulvovaginal candidiasis, bacterial vaginosis with secondary vestibular inflammation, herpes simplex outbreaks, and trichomoniasis can all produce entry pain. A vaginal wet mount, pH test, and nucleic acid amplification testing (NAAT) for STIs will identify these causes.

Dermatologic conditions. Lichen sclerosus and lichen planus cause vulvar architectural changes, adhesions, and fissuring. Untreated lichen sclerosus carries a 4-6% lifetime risk of vulvar squamous cell carcinoma, making biopsy appropriate for any non-resolving lesion [10].

Causes of Deep Painful Intercourse

Deep dyspareunia signals pathology at or above the level of the cervix. The workup shifts from vulvar inspection to bimanual exam and imaging.

Endometriosis. This is the leading cause of deep dyspareunia in premenopausal women. A 2022 meta-analysis in Human Reproduction Update (42 studies, N=10,921) found that 62% of women with laparoscopically confirmed endometriosis reported deep dyspareunia, compared to 18% of controls [11]. Pain is often position-dependent and worsens perimenstrually. Deep infiltrating endometriosis of the uterosacral ligaments and rectovaginal septum is particularly associated with pain during thrusting.

Adenomyosis. Formerly considered a diagnosis of exclusion, MRI and high-resolution transvaginal ultrasound now identify adenomyosis with sensitivity above 80% [12]. The condition produces a boggy, tender uterus, heavy menses, and deep pelvic pain with intercourse.

Pelvic inflammatory disease. Acute or chronic PID from Chlamydia trachomatis or Neisseria gonorrhoeae causes cervical motion tenderness and adnexal pain. The CDC 2021 STI Treatment Guidelines recommend empiric treatment with ceftriaxone 500 mg IM once plus doxycycline 100 mg orally twice daily for 14 days when clinical suspicion is moderate to high [13].

Interstitial cystitis/bladder pain syndrome (IC/BPS). Suprapubic and urethral pain that worsens with bladder filling and intercourse characterizes IC/BPS. The American Urological Association (AUA) guideline estimates prevalence at 2.7-6.5% of U.S. women, with dyspareunia reported in up to 78% of those diagnosed [14].

Ovarian pathology and fibroids. Large ovarian cysts, particularly endometriomas, and subserosal or pedunculated fibroids can produce positional deep pain during intercourse. Pelvic ultrasound is the first-line imaging study.

Painful Intercourse in Men

Male dyspareunia is underrecognized. Phimosis (tight foreskin causing pain on retraction) is the most common structural cause and responds to topical betamethasone 0.05% cream applied twice daily for 4-8 weeks, with circumcision reserved for refractory cases [15].

Peyronie disease, characterized by fibrous plaques in the tunica albuginea causing penile curvature and pain, affects an estimated 3-9% of adult men. The 2023 AUA/Sexual Medicine Society of North America (SMSNA) guideline notes that intralesional collagenase clostridium histolyticum (Xiaflex) is the only FDA-approved pharmacotherapy and reduces curvature by a mean of 17 degrees in the IMPRESS I and II trials (N=832) [16].

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS, NIH category III) produces perineal, suprapubic, or ejaculatory pain. Pelvic floor physical therapy and multimodal phenotyping using the UPOINT system guide treatment. Alpha-blockers such as tamsulosin 0.4 mg daily may reduce symptoms in men with voiding dysfunction [17].

How Painful Intercourse Is Diagnosed

A structured approach prevents missed diagnoses and avoids unnecessary procedures.

History. Clinicians should ask: Is the pain at the opening or deep inside? Does it occur with every attempt or only certain positions? Is it lifelong or acquired? Is there associated bleeding, discharge, or urinary symptoms? Dr. Andrew Goldstein, director of the Centers for Vulvovaginal Disorders, has noted: "Three questions can triage 80% of dyspareunia cases before you even begin the exam. Where is the pain, when did it start, and does it occur outside of intercourse?" [18].

Physical exam. The cotton-swab test maps vestibular tenderness. A single-digit vaginal exam assesses pelvic floor tone before proceeding to a speculum exam and bimanual palpation. Uterosacral nodularity on rectovaginal exam raises suspicion for deep infiltrating endometriosis.

Laboratory and imaging. Vaginal pH, wet mount, yeast culture, and NAAT for Chlamydia and Gonorrhea address infectious causes. Transvaginal ultrasound evaluates ovarian, uterine, and adnexal pathology. MRI is reserved for suspected deep infiltrating endometriosis or adenomyosis when ultrasound findings are equivocal.

Referral triggers. Patients with refractory vestibulodynia, suspected endometriosis, or complex pelvic floor dysfunction benefit from referral to a sexual medicine specialist, pelvic floor physical therapist, or minimally invasive gynecologic surgeon.

Treatment Options by Cause

Treatment for dyspareunia is cause-specific. No single therapy addresses all etiologies, and a "try this lubricant" approach without diagnosis delays effective care.

For GSM/vaginal atrophy: vaginal estrogen remains the gold standard. A 2023 randomized trial in JAMA Internal Medicine (N=302) confirmed that vaginal estradiol 10 mcg tablets used twice weekly for 12 weeks produced significant improvement in dyspareunia severity scores compared with vaginal moisturizer alone (mean change -1.4 vs. -0.6 on a 4-point scale, P<0.001) [19]. Prasterone (Intrarosa, 6.5 mg vaginal insert nightly), a DHEA-based option, is FDA-approved for moderate-to-severe GSM dyspareunia and works through local conversion to estrogen and testosterone [20].

For provoked vestibulodynia: first-line therapy is pelvic floor physical therapy combined with topical lidocaine 5% ointment applied 15-20 minutes before intercourse. Second-line options include low-dose tricyclic antidepressants (amitriptyline 10-25 mg nightly) or compounded topical formulations. Vestibulectomy (surgical excision of the painful vestibular mucosa) has the highest response rate at 85-93% in case series, but is reserved for refractory PVD [7].

For endometriosis-related deep pain: hormonal suppression with combined oral contraceptives (continuous use), progestins (dienogest 2 mg daily or norethindrone acetate 5 mg daily), or GnRH antagonists (elagolix 150-200 mg daily) reduces pain. The Phase III ELARIS EM-I and EM-II trials (combined N=1,686) showed that elagolix 200 mg twice daily reduced dyspareunia scores by 50.3% at 6 months versus 32.5% with placebo [21]. Laparoscopic excision of deep infiltrating endometriosis offers the best long-term outcomes for anatomically defined disease.

For vaginismus/hypertonic pelvic floor: graduated vaginal dilator therapy under the guidance of a pelvic floor physical therapist, combined with cognitive behavioral therapy (CBT) for the fear-avoidance cycle, is first-line. Botulinum toxin A injection into the levator ani (50-150 units) has shown promise in small trials for refractory cases [22].

For infections: targeted antimicrobial therapy. Recurrent vulvovaginal candidiasis (four or more episodes per year) may warrant a 6-month fluconazole suppression regimen (150 mg weekly) per the 2021 CDC guidelines [13].

When to Seek Urgent Evaluation

Certain presentations require prompt medical assessment rather than watchful observation.

New-onset deep pelvic pain with fever, abnormal discharge, or cervical motion tenderness suggests acute PID and warrants same-day empiric antibiotics. Postcoital bleeding in a woman over 40 or with an abnormal cervical screening history requires colposcopy to exclude cervical pathology. Rapid-onset vulvar pain with visible ulceration may indicate a herpes simplex outbreak, chancroid, or Behçet disease. A palpable pelvic mass discovered on exam needs urgent imaging.

Pain that worsens progressively over weeks to months, particularly if associated with bowel or bladder symptoms, should prompt evaluation for endometriosis, IC/BPS, or rarely, gynecologic malignancy. The ACOG committee opinion on chronic pelvic pain recommends against attributing persistent dyspareunia to psychological causes without first completing a thorough organic workup [5].

The Role of Psychological and Relational Factors

Pain during sex is never "just in your head," but the brain does modulate pain perception. Central sensitization, where the spinal cord and brain amplify pain signals from the pelvis, is documented in chronic vulvodynia and IC/BPS. A 2020 study in Pain (N=221 women with vestibulodynia) found that pain catastrophizing scores predicted dyspareunia severity independently of local tissue findings [23].

CBT and mindfulness-based interventions reduce pain-related distress and improve sexual function in controlled trials. Couples therapy that addresses avoidance behaviors and partner response patterns shows additional benefit. Dr. Caroline Pukall, professor of psychology at Queen's University and past president of the International Society for the Study of Women's Sexual Health, has stated: "Treating dyspareunia without addressing the relational and psychological context is like treating diabetes without discussing diet. You might control glucose with medication, but you miss half the picture" [24].

Validated instruments like the Female Sexual Function Index (FSFI) and the McGill Pain Questionnaire help track treatment response across both physical and psychosocial domains.